Effects of oral ELND005 (scyllo-inositol) on neuropsychiatric symptoms in a 78-week phase 2 study in mild/moderate Alzheimer's disease (AD): Potential role of myo-inositol reduction
Alzheimers & Dementia(2012)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要